Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Clinical Trials
746
Trial Phases
5 Phases
Drug Approvals
5
Clinical Trials
Distribution across different clinical trial phases (663 trials with phase data)• Click on a phase to view related trials
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1200
- Registration Number
- NCT07175428
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT07154745
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT07154290
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT07142343
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT07112378
- Locations
- 🇺🇸
GI Care for Kids LLC, Atlanta, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 71
- Next
News
Regeneron's Garetosmab Achieves 90% Reduction in Bone Formation in Rare Disease Trial
Regeneron's Phase 3 OPTIMA trial of garetosmab met its primary endpoint, demonstrating a 90% or greater reduction in new heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva at 56 weeks.
Ollin Biosciences Emerges with $100M to Challenge Leading Eye Disease Treatments
Ollin Biosciences launched with $100 million in Series A funding led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital to develop next-generation ophthalmology treatments.
Dualitas Therapeutics Emerges from Stealth with $65M Series A to Advance Bispecific Antibody Pipeline
Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.
Regeneron's Libtayo Combination Therapy Demonstrates 19.4% Five-Year Survival Rate in Advanced Lung Cancer
Regeneron's Phase 3 EMPOWER-Lung 3 trial shows Libtayo plus chemotherapy achieved a 19.4% five-year survival rate compared to 8.8% with chemotherapy alone in advanced non-small cell lung cancer patients.
Sandoz Secures Patent Settlement with Regeneron, Clears Path for Aflibercept Biosimilar Launch by End of 2026
Sandoz reached a patent settlement agreement with Regeneron resolving all litigation related to its FDA-approved aflibercept biosimilar Enzeevu, clearing the path for US market entry by the fourth quarter of 2026.
Regeneron's First-in-Class Allergen-Blocking Antibodies Show 52% Reduction in Cat Allergy Symptoms in Phase 3 Trials
Regeneron's investigational allergen-blocking antibodies achieved significant symptom reduction in Phase 3 trials, with cat allergy treatments reducing ocular itch by 52% and birch allergy treatments reducing itch by 51% compared to placebo.
Sanofi Shares Plummet 10% as Amlitelimab Phase III Data Falls Short of Dupixent Expectations
Sanofi's experimental atopic dermatitis drug amlitelimab met all primary endpoints in Phase III trials but showed weaker efficacy compared to the company's blockbuster drug Dupixent.
Merck KGaA Appoints David Weinreich as Global Head of R&D to Revitalize Healthcare Pipeline
Merck KGaA has appointed David Weinreich as Global Head of R&D and Chief Medical Officer for its Healthcare business sector, bringing over 20 years of experience and leadership in developing 15 approved drugs worldwide.
FDA Issues Form 483 to Novo Nordisk's Bloomington Plant Over Contamination and Safety Violations
The FDA issued a Form 483 to Novo Nordisk's Bloomington, Indiana manufacturing facility following an inspection that identified contamination issues including cat and human hair in vial stoppers and pest infestations in classified areas.
Immuneering Partners with Lilly for Phase 2 NSCLC Combination Trial Testing Dual MAPK Pathway Blockade
Immuneering Corporation announced a clinical supply agreement with Eli Lilly to evaluate atebimetinib in combination with olomorasib in a planned Phase 2 trial for advanced KRAS G12C-mutant non-small cell lung cancer patients.